权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Improving Adverse Event Reporting on Cooperative Oncology Group Trials

改进肿瘤学合作组试验的不良事件报告

基本信息

批准号：
10229395
负责人：
Tamara Porter Miller
金额：
$ 16.99万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-21 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10229395
关键词：
Acute Lymphocytic Leukemia Acute Myelocytic Leukemia Acute Renal Failure with Renal Papillary Necrosis Acute leukemia Adverse event Age Algorithms Award Chemotherapy-Oncologic Procedure Child Childhood Acute Myeloid Leukemia Childhood Leukemia Clinical Clinical Data Clinical Informatics Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Design Common Terminology Criteria for Adverse Events Complex Computerized Medical Record Consumption Creatinine Data Data Set Doctor of Philosophy Enrollment Environment Ethnic Origin Family Foundations Gender Goals Gold Hospitals Incidence Informatics Knowledge Laboratories Learning Malignant Childhood Neoplasm Manuals Medical Records Mentors Methods National Cancer Institute Natural Language Processing Oncology Group Patients Pediatric Hospitals Pediatric Oncology Pediatric Oncology Group Pennsylvania Pharmaceutical Preparations Philadelphia Positioning Attribute Predictive Value Process Publishing Race Reporting Research Resources Risk Risk Factors Safety Sensitivity and Specificity Supportive care System Testing Texas Text Time Toxicity due to chemotherapy Training Treatment Side Effects Universities Work Writing base cancer clinical trial cancer therapy career chemotherapy clinical decision-making clinical epidemiology clinical implementation cohort data pipeline epidemiology study experience implementation science improved leukemia nephrotoxicity novel oncology trial prospective secondary analysis side effect skills statistics symposium

项目摘要

PROJECT SUMMARY/ABSTRACT Background: The reports of side effects on clinical trials describe expected toxicities of chemotherapy. However, these side effects, also called adverse events, are globally under-reported on trials, which means that clinicians do not have an accurate sense of adverse event rates. In the current system, adverse events are identified through time-consuming, manual medical record review. This study aims to develop a system that uses electronic medical record data to capture complex adverse events of chemotherapy for pediatric cancer and to prove that this method is more accurate than the current adverse event reporting system. The specific aims of this application are to 1) develop algorithms to identify 10 complex adverse events using electronic medical record data from children treated for acute leukemia at two large children's hospitals, 2) compare the accuracy of this new method to that of the current system, and 3) demonstrate the utility of electronic adverse event capture in answering clinical questions by defining the incidence and risk factors of acute kidney injury. Methods: This study will use data from 1900 children with acute leukemia treated at the Children's Hospital of Philadelphia (CHOP) or the Texas Children's Hospital (TCH) from 2002 through 2017. Algorithms will be developed to identify adverse events by extracting electronic medical record data at CHOP. Once finalized, the algorithms will be tested at TCH. Using chart abstraction data as the gold standard, the accuracy of electronic ascertainment and of trial adverse event reports will determined, and the relative accuracy of each method will be compared. Lastly, algorithms will extract creatinine results from the electronic medical record and the incidence of acute kidney injury will be determined for each leukemia type and by chemotherapy regimen. Risk factors for acute kidney injury will be explored. Career Goals and Environment: With the support of this K07 award, the applicant, Tamara P. Miller, MD, MSCE, will learn how to use electronic medical record data for clinical research, obtain formal training in clinical informatics and implementation science, develop expertise in clinical trial design, and improve her knowledge of pediatric oncology and skills in scientific writing. To complete these training goals, Dr. Miller has assembled an experienced, complementary, and nurturing mentoring team led by her primary mentor, Richard Aplenc, MD, PhD. Her training plan includes formal coursework in informatics, tutorials, national conferences, and research progress and writing groups. She will benefit from the outstanding depth of resources and opportunities at CHOP and the University of Pennsylvania. Her long-term goal is to integrate the novel system of adverse event ascertainment she creates into pediatric oncology trials and to use the accurate datasets she develops to answer clinically important questions. With this award, Dr. Miller will be well-positioned to transition to her goal of an independent clinical research career focused on improving adverse event reporting and supportive care practices in pediatric oncology.

项目总结/文摘